Drugs / Flurpiridaz
Flurpiridaz
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04594941 | Jan → May 2022 | coronary artery disorder, myocardial ischemia | GE Healthcare | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03354273 | Jun 2018 → May 2022 | coronary artery disorder | GE Healthcare | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flurpiridaz | “Flurpiridaz (18F) Injection.” NCT03354273 ↗ |
| Known as | Fluorine-18 Flurpiridaz | “Positron emission tomography (PET) myocardial perfusion imaging (MPI) with the novel radiopharmaceutical Fluorine-18 Flurpiridaz” PMID 33521873 ↗ Jan 2021 |
| Known as | Flurpiridaz (18F) | “Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein” NCT03354273 ↗ |
| Known as | Flurpiridaz F-18 | “Flurpiridaz F-18 (flurpiridaz) is a novel positron emission tomography (PET) myocardial perfusion imaging tracer.” PMID 37821170 ↗ Oct 2023 |
| Modality | Diagnostic / imaging agent | “Flurpiridaz F-18 (flurpiridaz) is a novel positron emission tomography (PET) myocardial perfusion imaging tracer.” PMID 37821170 ↗ Oct 2023 |
| Route | Intravenous | “All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein” NCT03354273 ↗ |